1 Oner FA, Yurdakul S, Oner E, et al. Evaluation of the effect of L- thyroxin therapy on cardiac functions by using novel tissue doppler-derived indices in patients with subclinical hypothyroidism[J]. Acta Cardiol, 2011, 66(1): 47-55.
[2]
2 Rotondi M, Magri F, Chiovato L. Risk of coronary heart disease and mortality for adults with subclinical hypotyroidism[J]. JAMA, 2010, 304(22): 2481-2482.
[3]
3 Tagami T, Tamanaha T, Shimazu S, et al. Lipid profiles in the untreated patients with Hashimoto thyroiditis and the effects of thyroxine treatment on subclinical hypothyroldism with Hashimoto thyroiditis[J]. Endocr J, 2010, 57(1): 253-258.
[4]
4 Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES Ⅲ) [J]. J Clin Endocrinol Metab, 2002, 87 (2):489-499.
[5]
5 Wang F, Tan Y, Wang C, et al. Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones[J]. J Clin Endocrinol Metab, 2012, 97(8): 2724-2731.
[6]
6 Tian L, Song Y, Xing M, et al. A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway[J]. Hepatology, 2010, 52(4): 1401-1409.
[7]
7 Monzani F, Del GP, Caraccio N, et al. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of L-thyroxine treatment[J]. Clin Investig, 1993, 71(5): 367-371.
